UCL Cancer Institute Special Seminar

Special guest, Professor Roy Herbst, Yale Comprehensive Cancer Center, presents: 'Personalized Therapy for Advanced Non-Small Cell Lung Cancer: from BATTLE to Immunotherapy'. Wednesday 16th December, 12.00pm

The therapy for advanced non-small cell lung cancer has improved dramatically in recent years.  We have moved from an era of Cisplatin-based chemotherapy to the use of targeted therapy, immunotherapy, and their combinations.  Of equal importance is the evolution of more personalized tissue-based therapy used to guide choice.  This lecture will chronicle the 10+ year history of the development of biopsy-based treatments for lung cancer, evolving from the initial BATTLE trials to the Umbrella and Master Protocols of today. The dawn of immunotherapy will be discussed along with efforts designed to administer it in a more targeted way with the development of novel biomarker and combinations based on the work of the Yale Cancer Center/Smilow Cancer Hospital SPORE research team.

1. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Nature. 2014 Nov 27; 515; 7528
2. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Gettinger S, Herbst RS. Cancer J. 2014 Jul-Aug;20(4):281-9.

For further information visit https://medicine.yale.edu/cancer/patient/people/roy_herbst-2.profile

Hosted by Daniel Hochhauser

The seminar will be followed by a sandwich buffet lunch

Wednesday 16th December, 12.00pm

Location

UCL Cancer Institute
Courtyard Café
Paul O'Gorman Building 
72 Huntley Street
London, WC1E 6DD